Fisher & Paykel share price on watch following FY21 trading update

The Fisher & Paykel share price could be on watch following the release of its FY21 trading update. Strong demand for its products continue.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price could be on the move today, following the release of the company's FY21 trading update.

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems used for use in chronic and acute respiratory care, surgery and treatment of obstructive sleep apnea. The company's products are sold worldwide. 

Trading update

Strong demand has continued for the company's hospital respiratory care products due to the ongoing spread of the coronavirus pandemic around the world. 

For the first 4 months of the company's financial year to the end of July 2020, hospital hardware sales have increased with 390% constant currency revenue growth compared to the prior comparable period (pcp). Additionally, hospital consumables revenue has grown 48% and overall hospital product group revenue has grown 91% compared to the pcp and in constant currency terms. 

Global sales of invasive ventilation and Optiflow consumables in July have returned to similar levels seen in April. Revenue in geographic areas is being impacted by the amount of infections. More than half of Fisher & Paykel's Airvo (humidified high flow system) hardware sales are outside North America and Europe this financial year. 

Constant currency revenue growth in obstructive sleep apena (OSA) for the first 4 months of FY21 was 4% compared to pcp. The growth in home respiratory support is more than offsetting a decline in OSA flow generators. Homecare revenue growth is 5% in constant currency terms compared to the pcp.

Outlook

Significant uncertainty about the extent and duration of the impact of the coronavirus has led Fisher & Paykel to make some assumptions regarding its FY21 results.

The assumptions include global hospitalisations requiring respiratory support to steadily return normal by the end of the calendar year and countries around the world continue to build respiratory care infrastructure. Additionally, it is assuming sleep apnea diagnosis rates are reduced for the year and freight costs remain elevated, resulting in a 200 basis points reduction in gross margin in constant currency for the year.

 "On this basis and at current exchange rates, full year operating revenue for the 2021 financial year would be approximately NZ$1.61 billion and net profit after tax would be approximately NZ$365 million to NZ$385 million" said Managing Director and CEO Lewis Gradon.

About the Fisher & Paykel share price

In its FY20 results released to the market on 29 June 2020, operating revenue was NZ$1.26 billion and net profit after tax was NZ$287.3 million.

The Fisher & Paykel share price has been a major beneficiary from the demand for its products during the coronavirus pandemic. As a result, its share price has surged 111.42% in the past year and is currently trading at $31.84.

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young investor working on his ASX shares portfolio on his laptop.
Share Market News

Dexus issues $500 million in new subordinated notes to boost flexibility

Dexus has priced A$500 million in subordinated notes to support investment opportunities and strengthen its funding base.

Read more »

person holding hat
Broker Notes

3 ASX 200 large-cap shares just re-rated by analysts

We reveal the latest views on an ASX 200 large-cap miner, retailer, and consumer staples leader.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Down 80% in 2025: Is it time to buy this beaten down ASX stock?

Let's see what Bell Potter is saying about this stock after its heavy decline.

Read more »

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Broker Notes

NextDC shares jump 11% on major OpenAI deal

This data centre operator will be home to the AI giant in Australia.

Read more »

Businesswoman holds hand out to shake.
Mergers & Acquisitions

These two takeover targets are still trading below their potential bid prices

Takeovers can provide windfall gains for investors, if they get in at the right price.

Read more »

two people sit side by side on a rollercoaster ride with their hands raised in the air and happy smiles on their faces
Opinions

Up over 200% in 6 months: Are Pilbara Minerals shares still a buy?

How high can the lithium producer’s shares go?

Read more »

A senior couple sets at a table looking at documents as a professional looking woman sits alongside them as if giving retirement and investing advice.
Share Market News

Fletcher Building updates funding: repays USPP, extends bank facilities

Fletcher Building further simplifies its funding structure by repaying USPP notes and extending debt facilities in December 2025.

Read more »

A large clear wine glass on the left of the image filled with fifty dollar notes on a timber table with a wine cellar or cabinet with bottles in the background.
Broker Notes

Macquarie names 3 top dividend-paying ASX 200 shares to buy today

Macquarie expects these three dividend paying ASX 200 shares to outperform in 2026. Let’s see why.

Read more »